Publications by authors named "Israel Ramos"

Claim this Profile
B
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern.
Adonis A Rubio, Viren A Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E Abernathy, Israel Ramos

Sci Transl Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite Stable Colorectal Cancer Metastasis in Combination with Immune Checkpoint Therapy in Mice.
Daniele V F Tauriello, Elena Sancho, Daniel Byrom, Carolina Sanchez-Zarzalejo, Maria Salvany, Israel Ramos

ACS Pharmacol Transl Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.
Adonis A Rubio, Viren A Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E Abernathy, Israel Ramos

bioRxiv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M Receptor Antagonist/ -Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile.
Mònica Aparici, Carla Carcasona, Israel Ramos, José Luís Montero, Raquel Otal

J Pharmacol Exp Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abediterol (LAS100977), an inhaled long-acting β-adrenoceptor agonist, has a fast association rate and long residence time at receptor.
Israel Ramos, Mònica Aparici, Maria Letosa, Carlos Puig, Amadeu Gavaldà

Eur J Pharmacol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β-adrenoceptor agonist (MABA) molecule.
Mònica Aparici, Carla Carcasona, Israel Ramos, José Luís Montero, José Luís Ortiz

Pulm Pharmacol Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Mònica Aparici, Amadeu Gavaldà, Israel Ramos, Carla Carcasona, Raquel Otal

Eur J Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl amides as potent and long acting muscarinic antagonists.
Maria Prat, María Antonia Buil, Maria Dolors Fernández, Laia Tort, Juan Manuel Monleón, Israel Ramos

Bioorg Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Amadeu Gavaldà, Israel Ramos, Carla Carcasona, Elena Calama, Raquel Otal

Pulm Pharmacol Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Mònica Aparici, Mireia Gómez-Angelats, Dolors Vilella, Raquel Otal, Carla Carcasona, Israel Ramos

J Pharmacol Exp Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
Maria Prat, María Antonia Buil, Maria Dolors Fernández, Jordi Castro, Juan Manuel Monleón, Israel Ramos

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.
Sonia Sentellas, Israel Ramos, Joan Albertí, Miquel Salvà, Francisca Antón

Eur J Pharm Sci· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Amadeu Gavaldà, Montserrat Miralpeix, Israel Ramos, Raquel Otal, Cristina Carreño

J Pharmacol Exp Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).
María Prat, Dolors Fernández, M Antonia Buil, María I Crespo, Gaspar Casals, Israel Ramos

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis